IBIO · Insider Trading
iBio, Inc. Common Stock
Every open-market purchase and sale reported by IBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Antonio Bernardino Guimaraes Parada | Director | A | +38,000 deriv. | — |
| 2026-10-15 | David Arkowitz | Director | A | +38,000 deriv. | — |
| 2026-10-15 | William D Clark | Director | A | +38,000 deriv. | — |
| 2026-10-15 | Elizabeth Stoner | Director | A | +38,000 deriv. | — |
| 2026-10-15 | Alexandra Kropotova | Director | A | +38,000 deriv. | — |
| 2026-10-15 | Gary Sender | Director | A | +38,000 deriv. | — |
| 2026-08-04 | Molly Carr | Chief Medical Officer | A | +430,000 deriv. | — |
| 2026-05-19 | Elizabeth Stoner | Director | A | +60,000 deriv. | — |
| 2026-03-27 | Marc Banjak | Chief Legal Officer | Buy | +13,934 | +$23.06K |
| 2026-03-23 | Felipe Duran | Chief Financial Officer | Buy | +24,835 | +$50.13K |
| 2026-03-23 | Martin Brenner | See Remarks | Buy | +12,336 | +$24.92K |
| 2026-01-30 | Martin Brenner | See Remarks | A | +479,000 deriv. | — |
| 2026-01-30 | Marc Banjak | Chief Legal Officer | A | +146,000 deriv. | — |
| 2026-01-30 | Felipe Duran | Chief Financial Officer | A | +179,000 deriv. | — |
| 2025-11-24 | Gary Sender | Director | A | +13,500 deriv. | — |
| 2025-11-24 | Alexandra Kropotova | Director | A | +13,500 deriv. | — |
| 2025-11-24 | Evert B. Schimmelpennink | Director | A | +13,500 deriv. | — |
| 2025-11-24 | Antonio Bernardino Guimaraes Parada | Director | A | +13,500 deriv. | — |
| 2025-11-24 | William D Clark | Director | A | +13,500 deriv. | — |
| 2025-11-24 | David Arkowitz | Director | A | +13,500 deriv. | — |
| 2025-10-22 | Felipe Duran | Chief Financial Officer | A | +75,000 deriv. | — |
| 2025-10-22 | Marc Banjak | Chief Legal Officer | A | +55,000 deriv. | — |
| 2025-10-22 | Martin Brenner | See Remarks | A | +180,000 deriv. | — |
| 2025-02-24 | Martin Brenner | See Remarks | A | +230,700 deriv. | — |
| 2025-02-24 | Felipe Duran | Chief Financial Officer | A | +84,700 deriv. | — |
| 2025-02-24 | Marc Banjak | Chief Legal Officer | A | +71,000 deriv. | — |
| 2025-01-13 | Martin Brenner | See Remarks | Buy | +9,191 | +$25.00K |
| 2025-01-13 | William D Clark | Director | Buy | +1,838 | +$5.00K |
| 2025-01-13 | Gary Sender | Director | Buy | +9,191 | +$25.00K |
| 2025-01-13 | Marc Banjak | Chief Legal Officer | Buy | +9,191 | +$25.00K |
| 2025-01-13 | Felipe Duran | Chief Financial Officer | Buy | +9,191 | +$25.00K |
| 2025-01-13 | David Arkowitz | Director | Buy | +18,382 | +$50.00K |
| 2025-01-13 | Antonio Bernardino Guimaraes Parada | Director | Buy | +183,823 | +$500.00K |
| 2024-12-09 | Antonio Bernardino Guimaraes Parada | Director | A | +12,600 deriv. | — |
| 2024-11-25 | Alexandra Kropotova | Director | A | +18,900 deriv. | — |
| 2024-11-25 | Gary Sender | Director | A | +18,900 deriv. | — |
| 2024-11-25 | David Arkowitz | Director | A | +12,600 deriv. | — |
| 2024-11-25 | William D Clark | Director | A | +18,900 deriv. | — |
| 2024-11-25 | Evert B. Schimmelpennink | Director | A | +18,900 deriv. | — |
| 2024-05-13 | Felipe Duran | Chief Financial Officer | A | +90,000 deriv. | — |
| 2024-05-13 | Martin Brenner | See Remarks | A | +257,300 deriv. | — |
| 2024-04-26 | Felipe Duran | Chief Financial Officer | A | +35,800 deriv. | — |
| 2023-11-03 | Martin Brenner | See Remarks | Sell | −4,881 | −$1.30K |
| 2023-10-05 | Martin Brenner | See Remarks | Sell | −5,267 | −$1.59K |
| 2023-10-03 | Martin Brenner | See Remarks | Sell | −4,215 | −$1.31K |
| 2023-08-30 | Martin Brenner | See Remarks | Sell | −5,011 | −$1.53K |
| 2023-08-24 | Felipe Duran | Chief Financial Officer | A | +60,000 deriv. | — |
| 2023-08-24 | Martin Brenner | See Remarks | A | +120,000 deriv. | — |
| 2023-07-28 | Martin Brenner | See Remarks | Sell | −4,515 | −$2.31K |
| 2023-07-13 | Martin Brenner | See Remarks | Sell | −47,020 | −$27.52K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Antonio Bernardino Guimaraes Parada | Director | 183,823 | $129.96K |
| Felipe Duran | Chief Financial Officer | 35,974 | $25.43K |
| Martin Brenner | See Remarks | 30,652 | $21.67K |
| Marc Banjak | Chief Legal Officer | 25,000 | $17.68K |
| David Arkowitz | Director | 18,382 | $13.00K |
| Gary Sender | Director | 9,191 | $6.50K |
| William D Clark | Director | 1,838 | $1.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.